Dr. Trinh on Re-Establishing Standard Surgical Procedures in Prostate Cancer

Video

In Partnership With:

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Quoc-Dien Trinh, MD, an associate professor of surgery at Harvard Medical School; co-director of the Dana-Farber/Brigham and Women's Prostate Cancer Center; and director of the Ambulatory Clinical Operations in the Division of Urological Surgery at Brigham and Women’s Hospital, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 (COVID-19) pandemic. 

In March 2020, many patients with indolent cancers had their surgeries safely postponed due to the COVID-19 pandemic, Trinh explains. In general, patients were understanding of this, and accepted that postponing surgery could minimize their risk of contracting or spreading the virus.

Now, surgeries are beginning to pick back up, particularly with regard to high-priority procedures, Trinh says.

However, according to Trinh, patients are more reluctant to undergo surgery as they do not feel ready to return to the hospital.

As such, it is important to re-establish patients’ trust and inform them of any measures that have been implemented to ensure their safety in the operating room, Trinh concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS